Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02616393

Enrollment

Registered

2015-11-26

Start date

2015-11-30

Completion date

2018-04-03

Last updated

2022-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Metastases, Leptomeningeal Metastases, Non-Small Cell Lung Cancer

Brief summary

A study to assess the activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations who have disease progression with Brain Metastases (BM) or Leptomeningeal Metastases (LM) or who have either BM or LM at initial presentation (IP)

Detailed description

This was a multicenter, phase 2, open-label study to assess the activity of tesevatinib, in subjects with non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations, and brain metastases (BM) or leptomeningeal metastases (LM). After completion of the screening assessments and confirmation of study eligibility, tesevatinib was orally administered to all subjects at a dose of 300 mg once daily (QD). Tumor response, both in the central nervous system (CNS) and outside the central nervous system (non-CNS), was assessed after the second cycle of treatment and then at the end of every two cycles of treatment thereafter. Subjects were treated with tesevatinib 300 mg QD until disease progression or the subject experienced unacceptable toxicity. Subjects who discontinued tesevatinib therapy were followed for survival. Subjects with NSCLC + EGFR mutations were assigned to one of three cohorts: * Cohort A: Brain Metastases (BM). Subjects had progressed with BM. * Cohort B: Leptomeningeal Metastases (LM). Subjects had initially presented or progressed with LM. * Cohort C: Brain Metastases at Initial Presentation (BM-IP). Subjects had no prior systemic therapy. Each of the three cohorts was to have 20 subjects, for a total of 60 subjects. All three cohorts were enrolled simultaneously. The primary objectives were to include: * Clinical activity of tesevatinib of subjects in Cohort A (BM) and Cohort C (BM-IP) as measured by Response Criteria in Solid Tumors (RECIST) version 1.1 which evaluated changes in BM size. * Clinical activity of tesevatinib of subjects in Cohort B (LM) as measured by improvement in Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 symptoms and signs. Efficacy assessments included response to treatment using RECIST criteria, progression-free survival (PFS), time to progression (TTP), overall survival (OS), and Quality of Life (QOL) questionnaires. Safety assessments included adverse event (AE) monitoring, electrocardiogram (ECG), Eastern Cooperative Oncology Group (ECOG) Performance Status, laboratory testing, physical examination, vital signs, and pregnancy testing. In addition, pharmacokinetic (PK) and pharmacodynamic (PD) assessments were performed. An End of Treatment Visit occurred within 3 days after the subject's last dose of study drug. This could have occurred at the visit when disease progression was diagnosed. Subjects were continued to be followed for disease progression and survival. A follow-up visit occurred 30 days (± 5 days) after the last dose of study drug. This visit may have occurred prior to 30 days if a new therapy was started within 30 days of last dose of study drug. For long-term follow-up, after subjects withdrew from the active treatment portion of the study, they were contacted by telephone every 8 weeks to assess survival status and any subsequent anti-cancer treatment.

Interventions

DRUGTesevatinib

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Cohort A Inclusion Criteria: * History of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation or an EGFR activating mutation that has had a clinical response to erlotinib, afatinib, or gefitinib in the patient being enrolled * Occurrence or progression of BM while receiving first-line therapy (either erlotinib, afatinib, or gefitinib) for at least 14 days. Patients may have received osimertinib (or other agents inhibiting the T790M EGFR mutation) as second line therapy. If BM progression occurs after osimertinib, patient will be eligible. * At least one measurable BM by RECIST 1.1 criteria (≥ 10 mm in longest diameter). Target lesions must not have received stereotactic radiotherapy (SRS). If a subject had prior whole brain radiotherapy (WBRT), progression in any measurable BM lesion must have occurred at least 3 months after the end of WBRT. Subjects with asymptomatic brain metastases may have been enrolled without prior radiation therapy to the brain. Subjects with minimally symptomatic brain metastases may have been enrolled without prior radiation therapy to the brain if they do not require immediate surgical or radiation therapy in the opinion of the treating investigator and in the opinion of a radiation therapy or neurosurgical consultant * Subjects in Cohort A may have had asymptomatic LM detected by MRI. (Subjects with symptoms or signs attributed to LM were enrolled in Cohort B whether or not they have brain metastases) * No clinically significant progression outside of the CNS on most recent EGFR inhibitor therapy * ECOG Score ≤ 2 * No history of another malignancy in the 5 years prior to study entry, except treated non-melanoma skin cancer or superficial bladder cancer or carcinoma in situ of the cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and have not recurred * Adequate organ and bone marrow functions * Serum potassium and magnesium levels above the lower limit of normal * No coexisting medical problems of sufficient severity to limit compliance with the study * Willing and able to sign written informed consent and able to comply with the study protocol for the duration of the study * Women of childbearing potential (i.e., menstruating women) must have had a negative urine pregnancy test (positive urine tests confirmed by serum test)

Exclusion criteria

* First day of dosing with tesevatinib less than 2 weeks from the last treatment of cytotoxic chemotherapy, biological therapy, or immunotherapy, and less than 6 weeks for nitrosoureas and mitomycin C. Surgical procedures must have been performed at least 2 weeks prior to the start of study treatment. Subjects must have recovered from the reversible effects of prior lung cancer treatments, including surgery and radiation therapy (excluding alopecia). * First day of dosing with tesevatinib less than 4 weeks from the last radiotherapy of the brain or spinal cord/cauda equina * First day of dosing with tesevatinib less than 2 weeks from treatment with another investigational agent * Treatment with erlotinib must have been discontinued at least 3 days prior to first dose of tesevatinib and treatment with afatinib or other tyrosine kinase inhibitor must have been discontinued at least 3 days prior to first dose of tesevatinib * Any concurrent therapy for BM other than the specified treatment in this study * Taking any medication known to moderately or severely inhibit the CYP3A4 isozyme or any drugs that are CYP3A4 inducers (including anti-epileptic agents such as phenytoin). A stable regimen (≥ 4 weeks) of antidepressants of the selective serotonin uptake inhibitor (SSRI) class was allowed (common SSRIs include escitalopram oxalate, citalopram, fluvoxamine, paroxetine, sertraline, and fluoxetine) * Taking any drugs associated with torsades de pointes or known to moderately or severely prolong the QTc(F) interval * Evidence of active heart disease such as myocardial infarction within the 3 months prior to study entry; symptomatic coronary insufficiency congestive heart failure; moderate or severe pulmonary dysfunction * History of torsades de pointes, ventricular tachycardia or fibrillation, pathologic sinus bradycardia (\< 50 bpm), heart block (excluding first degree block, being PR interval only), or congenital long QT syndrome. Subjects with a history of atrial arrhythmias were discussed with the medical monitor * Had an active infectious process * Female subject pregnant or lactating * Known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign body * Marked prolongation of QTc(F) interval at screening or baseline (QTc\[F\] interval \> 470 msec) using the Fridericia method of correction for heart rate * Gastrointestinal (GI) condition interfering with drug absorption * Non-malignant neurological disease that would interfere with evaluation of symptoms or signs of brain metastases Cohort B Inclusion Criteria: * History of NSCLC with EGFR mutation (either exon 19 deletion or L858R mutation) or, if previously treated, history of an activating EGFR mutation that had a clinical response to erlotinib, afatinib, or gefitinib in the subject being enrolled). * Presentation with LM at initial presentation with no prior systemic treatment, or occurrence or progression of LM while receiving first-line therapy (either erlotinib, afatinib, or gefitinib) for at least 14 days. Patients may have received osimertinib (or other agents inhibiting the T790M EGFR mutation) as second line therapy. If LM progression occurred after osimertinib, subjects were eligible. * Presence of at least one CTCAE 4.03 symptom/sign of at least Grade 1 attributed by the investigator to LM * Diagnosis of LM by: 1. Cytological evidence in cerebrospinal fluid (CSF) sample of LM due to NSCLC, and/or 2. Findings on gadolinium-enhanced MRI * No clinically significant progression outside of the CNS on most recent EGFR inhibitor therapy * Concomitant brain metastases and brain metastases previously treated with radiation therapy were allowed. (Subjects with symptoms or signs attributed to LM will be enrolled in Cohort B whether or not they have brain metastases) * ECOG Score ≤ 2 * No history of another malignancy in the 5 years prior to study entry, except treated non-melanoma skin cancer or superficial bladder cancer or carcinoma in situ of the cervix or Stage 1 or 2 cancers of other sites that have been treated surgically and had not recurred * Adequate organ and bone marrow functions * Serum potassium and magnesium levels above the lower limit of normal (LLN) * No coexisting medical problems of sufficient severity to limit compliance with the study * Willing and able to sign written informed consent and able to comply with the study protocol for the duration of the study * Women of childbearing potential (i.e., menstruating women) must have had a negative urine pregnancy test (positive urine tests confirmed by serum test)

Design outcomes

Primary

Measure	Time frame	Description
Best Overall Response Rate (ORR) of Subjects With BM	Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first	The best overall response rates (ORRs) of subjects who had brain tumors and exhibited either a complete response (CR) or a partial responder (PR) to therapy divided by the total number of subjects treated with tesevatinib 300 mg PO QD. Response rates are in accordance with RECIST Version 1.1 criteria. Since such brain metastases (BM) tumors can either affect the central nervous system (CNS) or not affect the CNS (non-CNS), they were categorized into CNS and non-CNS subsets. Because leptomeningeal metastases (LM) only are considered cancer cell migration from the breast, lung, or some other part of the body to the cerebrospinal fluid (CSF), analysis of CNS are not appropriate, so Cohort B is excluded.
Best ORR of Subjects With LM	Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first	The best overall response rates (ORRs) of subjects who had leptomeningeal tumors and exhibited either a complete response (CR) or a partial responder (PR) to therapy divided by the total number of subjects treated with tesevatinib 300 mg PO QD. Response rates are in accordance with RECIST Version 1.1 criteria. Since leptomeningeal metastases (LM) are only considered cancer cell migration from the breast, lung, or some other part of the body to the cerebrospinal fluid (CSF), analysis of CNS are not appropriate, so Cohorts A and C are excluded.

Secondary

Measure	Time frame	Description
Probability of PFS at 24 Weeks--Cohort C (BM-IP Only)	24 weeks (6 months)	Probability that subjects with brain metastases at initial presentation (BM-IP) would not progress, i.e., progression-free survival (PFS) after 24 weeks (6 months) of treatment with tesevatinib 300 mg PO QD
Probability of OS at 12 Weeks and at 24 Weeks--Cohort A (BM Only) and Cohort B (LM Only)	24 weeks (6 months)	Probability that subjects with brain metastases (BM) or leptomeningeal metastases (LM) survived (overall survival \[OS\]) after 12 weeks (3 months) and after 24 weeks (6 months) of treatment with tesevatinib 300 mg PO QD
Median Time to Progression (TTP)--Cohort A (BM), Cohort B (LM), Cohort C (BM-IP)	Until disease progression, death, unacceptable toxicity, or up to 2 years, whichever occurred first	Median time to the development of disease progression (TTP) for subjects in Cohort A, Cohort B and Cohort C who were treated with tesevatinib 300 mg PO QD
Median Progression-free Survival (PFS)	Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first	Median duration of survival without progression of subjects treated with tesevatinib 300 mg PO QD.
Probability of TTP at 24 Weeks--CNS	24 weeks (6 months)	Probability that the time to progression (TTP) for subjects with metastases to the central nervous system (CNS) would be at 24 weeks (6 months) of therapy with tesevatinib 300 mg PO QD.
Quality of Life (QoL): Mean Change From Baseline in EORTC-QLQ-C30 Questionnaire Scores	Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first	The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Cancer 30 (C30) is a 30-question assessment composed of both multi-item scales and single-item measures: 5 functional scales, 3 symptom scales, 1 global QoL scale, and 6 single items. Ratings are on a 4-point scale (not at all, a little quite a bit, very much), with scoring from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. The outcome measure is the mean change in the EORTC-QLQ-C30 from baseline to a visit.
Quality of Life (QoL): Mean Change From Baseline in EORTC-QLQ-BN20 Questionnaire Scores	Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first	The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Cancer BN20 Questionnaire is a 20-question assessment of symptomatology based on a categorical scale (Not at all = 1; A little = 2; Quite a bit = 3; and Very much = 4). For 20 questions: minimum score = 20 and maximum score = 80. Higher scores indicate greater level of symptomatology/problems. The outcome measure is the mean change in the EORTC-QLQ-BN20 from baseline to a visit.
Probability of TTP at 12 Weeks and 24 Weeks--Non-CNS Cohort A (BM Only) and Cohort B (LM Only)	24 weeks (6 months)	Probability that the time to progression (TTP) for subjects with no metastases to the central nervous system (non-CNS) in Cohort A (brain metastases only) or Cohort B (leptomeningeal metastases only) would be at 12 weeks (3 months) and at 24 weeks (6 months) of therapy with tesevatinib 300 mg PO QD. There were an insufficient number of subjects in Cohort C (brain metastases at initial presentation) who had events.
Probability of PFS at 12 Weeks and 24 Weeks--Cohort A (BM Only) and Cohort B (LM Only)	24 weeks (6 months)	Probability that subjects with brain metastases (BM) or leptomeningeal metastases (LM) would not progress, i.e., progression-free survival (PFS) after 12 weeks (3 months) and after 24 weeks (6 months) of treatment with tesevatinib 300 mg PO QD

Countries

United States

Participant flow

Participants by arm

Arm	Count
Cohort A - Brain Metastases Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC who have progressed with BM Tesevatinib	13
Cohort B - Leptomeningeal Metastases Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC who have progressed with LM Tesevatinib	20
Cohort C - Brain Metastases at Initial Presentation Tesevatinib will be orally administered with a dose of 300 mg once daily to subjects with NSCLC with BM at initial presentation Tesevatinib	3
Total	36

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Overall Study	Death	5	12	1
Overall Study	Lost to Follow-up	0	2	0
Overall Study	Other	3	0	0
Overall Study	Termination by Sponsor	4	5	2
Overall Study	Withdrawal by Subject	1	1	0

Baseline characteristics

Characteristic	Cohort B - Leptomeningeal Metastases	Cohort C - Brain Metastases at Initial Presentation	Cohort A - Brain Metastases	Total
Age, Continuous	56.3 years	64.7 years	60.7 years	58.6 years
EORTC-QLQ-BN20 Questionnaire	37.7 Units (score) on a scale STANDARD_DEVIATION 8.64	22.0 Units (score) on a scale STANDARD_DEVIATION 2	34.0 Units (score) on a scale STANDARD_DEVIATION 15.71	35.1 Units (score) on a scale STANDARD_DEVIATION 11.89
EORTC-QLQ-C30 Questionnaire	66.5 Units (score) on a scale STANDARD_DEVIATION 12.84	51.7 Units (score) on a scale STANDARD_DEVIATION 5.51	59.2 Units (score) on a scale STANDARD_DEVIATION 20.48	62.7 Units (score) on a scale STANDARD_DEVIATION 60.6
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants	0 Participants	3 Participants	4 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	19 Participants	3 Participants	10 Participants	32 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	10 Participants	0 Participants	3 Participants	13 Participants
Race (NIH/OMB) Black or African American	2 Participants	2 Participants	2 Participants	6 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	4 Participants	4 Participants
Race (NIH/OMB) White	8 Participants	1 Participants	4 Participants	13 Participants
Sex: Female, Male Female	15 Participants	2 Participants	6 Participants	23 Participants
Sex: Female, Male Male	5 Participants	1 Participants	7 Participants	13 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	5 / 13	12 / 20	1 / 3	18 / 36
other Total, other adverse events	13 / 13	20 / 20	3 / 3	36 / 36
serious Total, serious adverse events	6 / 13	13 / 20	2 / 3	21 / 36

Outcome results

Primary

Best ORR of Subjects With LM

The best overall response rates (ORRs) of subjects who had leptomeningeal tumors and exhibited either a complete response (CR) or a partial responder (PR) to therapy divided by the total number of subjects treated with tesevatinib 300 mg PO QD. Response rates are in accordance with RECIST Version 1.1 criteria. Since leptomeningeal metastases (LM) are only considered cancer cell migration from the breast, lung, or some other part of the body to the cerebrospinal fluid (CSF), analysis of CNS are not appropriate, so Cohorts A and C are excluded.

Time frame: Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first

Arm	Measure	Value (NUMBER)
Cohort A (BM)	Best ORR of Subjects With LM	0 Percentage of participants (%)

Primary

Best Overall Response Rate (ORR) of Subjects With BM

The best overall response rates (ORRs) of subjects who had brain tumors and exhibited either a complete response (CR) or a partial responder (PR) to therapy divided by the total number of subjects treated with tesevatinib 300 mg PO QD. Response rates are in accordance with RECIST Version 1.1 criteria. Since such brain metastases (BM) tumors can either affect the central nervous system (CNS) or not affect the CNS (non-CNS), they were categorized into CNS and non-CNS subsets. Because leptomeningeal metastases (LM) only are considered cancer cell migration from the breast, lung, or some other part of the body to the cerebrospinal fluid (CSF), analysis of CNS are not appropriate, so Cohort B is excluded.

Time frame: Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first

Population: Subjects with BM only (Cohorts A and C). Subjects with LM (Cohort B) were excluded.

Arm	Measure	Group	Value (NUMBER)
Cohort A (BM)	Best Overall Response Rate (ORR) of Subjects With BM	non-CNS	0 Percentage of participants (%)
Cohort A (BM)	Best Overall Response Rate (ORR) of Subjects With BM	CNS	15.4 Percentage of participants (%)
Cohort A (BM)	Best Overall Response Rate (ORR) of Subjects With BM	CNS + non-CNS	15.4 Percentage of participants (%)
Cohort C (BM-IP)	Best Overall Response Rate (ORR) of Subjects With BM	non-CNS	100 Percentage of participants (%)
Cohort C (BM-IP)	Best Overall Response Rate (ORR) of Subjects With BM	CNS	100 Percentage of participants (%)
Cohort C (BM-IP)	Best Overall Response Rate (ORR) of Subjects With BM	CNS + non-CNS	100 Percentage of participants (%)
Overall BM	Best Overall Response Rate (ORR) of Subjects With BM	CNS	31.3 Percentage of participants (%)
Overall BM	Best Overall Response Rate (ORR) of Subjects With BM	CNS + non-CNS	31.3 Percentage of participants (%)
Overall BM	Best Overall Response Rate (ORR) of Subjects With BM	non-CNS	18.8 Percentage of participants (%)

Secondary

Median Progression-free Survival (PFS)

Median duration of survival without progression of subjects treated with tesevatinib 300 mg PO QD.

Time frame: Until disease progression, unacceptable toxicity, or up to 2 years, whichever occurred first

Arm	Measure	Value (MEDIAN)
Cohort A (BM)	Median Progression-free Survival (PFS)	9.29 Weeks
Cohort C (BM-IP)	Median Progression-free Survival (PFS)	10.86 Weeks
Overall BM	Median Progression-free Survival (PFS)	37.71 Weeks

Secondary

Median Time to Progression (TTP)--Cohort A (BM), Cohort B (LM), Cohort C (BM-IP)

Median time to the development of disease progression (TTP) for subjects in Cohort A, Cohort B and Cohort C who were treated with tesevatinib 300 mg PO QD

Time frame: Until disease progression, death, unacceptable toxicity, or up to 2 years, whichever occurred first

Arm	Measure	Value (MEDIAN)
Cohort A (BM)	Median Time to Progression (TTP)--Cohort A (BM), Cohort B (LM), Cohort C (BM-IP)	21.43 Weeks
Cohort C (BM-IP)	Median Time to Progression (TTP)--Cohort A (BM), Cohort B (LM), Cohort C (BM-IP)	8.14 Weeks
Overall BM	Median Time to Progression (TTP)--Cohort A (BM), Cohort B (LM), Cohort C (BM-IP)	34.93 Weeks

Secondary

Probability of OS at 12 Weeks and at 24 Weeks--Cohort A (BM Only) and Cohort B (LM Only)

Probability that subjects with brain metastases (BM) or leptomeningeal metastases (LM) survived (overall survival \[OS\]) after 12 weeks (3 months) and after 24 weeks (6 months) of treatment with tesevatinib 300 mg PO QD